Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

NCT02318082 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Chronic Versus Graft Host Disease

Interventions

DRUG: Interleukin-2

Sponsor

Dana-Farber Cancer Institute